4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
NuCana plc (NCNA) operates in the Biotechnology industry and is headquartered in Edinburgh, United Kingdom with about 10 employees. Its market capitalization is roughly $6 million. In the fiscal year ended 2025-12-31, NCNA reported £0M in revenue and (£29M) in net income.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | £0M | £0M | £0M | £0M |
| Operating Income (EBIT) | (£21M) | (£23M) | (£31M) | (£44M) |
| Net Income | (£29M) | (£19M) | (£28M) | (£32M) |
GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|---|
| Total Revenue | £0M | £0M | £0M | £0M | £0M |
| Operating Income (EBIT) | (£3M) | (£5M) | (£3M) | (£4M) | (£12M) |
| Net Income | (£3M) | (£4M) | (£2M) | (£0M) | (£24M) |
GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | £30M | £15M | £28M | £58M | — |
| Total Liabilities | £6M | £9M | £13M | £20M | — |
GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NCNA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms